Proanthocyanidin and Centella asiatica combination for atherosclerosis plaque stabilization

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments and prevention methods for atherosclerosis, particularly affecting arteries, are inadequate in effectively addressing the formation and progression of atherosclerotic plaques, which can lead to severe cardiovascular events such as heart attacks and strokes.

Innovation Solution

A combination of proanthocyanidins, preferably procyanidins, and Centella asiatica extracts, administered in a suitable excipient, is used to prevent or treat atherosclerosis, offering a synergistic effect that stabilizes atherosclerotic plaques and reduces the risk of cardiovascular events.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments and prevention methods are used for atherosclerosis, then some level of plaque management is achieved, but they are inadequate in effectively addressing the formation and progression of atherosclerotic plaques

Engineering Contradiction:
Improveeffectiveness of plaque stabilizationVSAvoidprogression of atherosclerosis
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent combines proanthocyanidins and Centella asiatica extracts into a single pharmaceutical composition to achieve synergistic effects. This merging of two distinct therapeutic agents addresses the inadequacy of conventional single-agent treatments, providing enhanced plaque stabilization and inhibition of atherosclerosis progression that neither agent achieves alone.

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The invention creates a composite pharmaceutical formulation integrating proanthocyanidins and Centella asiatica extracts. This composite approach leverages the complementary mechanisms of action between the two components - proanthocyanidins for antioxidant and anti-inflammatory effects, and Centella asiatica for fibrosis inhibition and plaque stabilization - to overcome the limitations of conventional monotherapies.

Inventive Principle:
Principle #40Composite materials

2Reliability

If proanthocyanidins and Centella asiatica are combined, then plaque stability is improved and cardiovascular risks are reduced, but the treatment complexity increases

Engineering Contradiction:
Improveplaque stabilityVSAvoidtreatment composition complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges proanthocyanidins and Centella asiatica extracts into a single integrated pharmaceutical composition, simplifying the treatment regimen despite the complexity of combining multiple active ingredients. This unified formulation delivers synergistic therapeutic effects for plaque stabilization while maintaining ease of administration as a single agent.

Inventive Principle:
Principle #5Merging (Combining)

Data Source

PatentUS9308230B2Combination of proanthocyanidins and centella asiatica for the treatment of atherosclerosis
Publication Date: 2016.04.12 HORPHAG RESEARCH IP (PYC) LTD

AI summary

The invention relates to a preparation for medical purposes and more specifically to a preparation consisting of the combination of proanthocyanidins such as Pycnogenol or grape seeds and Centella asiatica and/or extracts thereof, for use in the prevention or treatment of atherosclerosis.